Robert Kilkuskie

Director/Board Member at Michigan High Throughput Screening Center

Commercial Services

Profile

Robert Kilkuskie currently works at Michigan High Throughput Screening Center, as Executive Director from 2009 and National Institute of Health Policy, as Principal.

Robert Kilkuskie active positions

Companies	Position	Start
Michigan High Throughput Screening Center Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties.	Director/Board Member	-
National Institute of Health Policy	Corporate Officer/Principal	29/04/2010

All active positions of Robert Kilkuskie

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Robert Kilkuskie's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Michigan High Throughput Screening Center Michigan High Throughput Screening Center Miscellaneous Commercial ServicesCommercial Services Michigan High Throughput Screening Center develops screening technologies for drug discovery. It offers services to academic institutions, biotechnology & pharmaceutical companies, and government laboratories. The firm is a not-for-profit contract research organization. Its scientists has extensive experience in drug discovery research and have experience in developing, validating and implementing high throughput screening assays for a broad range of drug targets in central nervous system disease, inflammation, infectious diseases, and oncology. It also has an extremely diverse library containing 100,000 drug able compounds and requires no licensing fees or royalties.	Commercial Services
National Institute of Health Policy